Table 3.
Clinico-pathological predictors of invasive component in patients with preoperative needle biopsy-based diagnosis of DCIS
| Variable | Risk for invasive component | |||
|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | |||
| HR (95% CI) | p | HR (95% CI) | p | |
| Age (> 50) | 0.75 (0.36–1.59) | 0.458 | 0.82 (0.38–1.79) | 0.623 |
| US tumor size (> 2 cm) | 1.31 (0.61–2.82) | 0.489 | 1.40 (0.60–3.26) | 0.441 |
| US finding (mass) | 1.52 (0.19–12.10) | 0.693 | ||
| Mammographic finding (microcalcification) | 0.73 (0.34–1.56) | 0.416 | 0.83 (0.36–1.91) | 0.666 |
| Multifocality (present) | 0.95 (0.39–2.31) | 0.906 | ||
| Nuclear grade (high) | 2.39 (1.05–5.42) | 0.038 | 2.86 (1.14–7.14) | 0.025 |
|
Estrogen receptor (positive) |
0.66 (0.30–1.45) | 0.305 | ||
|
Progesterone receptor (positive) |
0.66 (0.31–1.38) | 0.266 | ||
| HER-2(overexpression) | 1.05 (0.49–2.22) | 0.904 | ||
| Ki-67 (> 14%) | 1.32 (0.48–3.62) | 0.589 | ||
|
Type of operation (Mastectomy) |
2.25 (1.00–5.05) | 0.050 | 2.27 (0.94–5.50) | 0.069 |
Abbreviations DCIS Ductal carcinoma in situ, US Ultrasonography, HER2 Human epidermal growth factor receptor 2